APO Research
Talk to an analyst

APO RESEARCH · REPORT

SARS-Cov-2 Vaccine (Vero Cell)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global SARS-Cov-2 Vaccine (Vero Cell) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025181 pages

Choose your research edition.

Industry ResearchSARS-Cov-2 Vaccine (Vero Cell) Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal SARS-Cov-2 Vaccine (Vero Cell) Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal SARS-Cov-2 Vaccine (Vero Cell) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SARS-Cov-2 Vaccine (Vero Cell) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal SARS-Cov-2 Vaccine (Vero Cell) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global SARS-Cov-2 Vaccine (Vero Cell) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for SARS-Cov-2 Vaccine (Vero Cell) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SARS-Cov-2 Vaccine (Vero Cell) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SARS-Cov-2 Vaccine (Vero Cell) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for SARS-Cov-2 Vaccine (Vero Cell) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of SARS-Cov-2 Vaccine (Vero Cell) include Sinopharm, Pfizer, WIBP, Sinovac Biotech, IMBCAMS,China and BIBP, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global SARS-Cov-2 Vaccine (Vero Cell) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SARS-Cov-2 Vaccine (Vero Cell) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SARS-Cov-2 Vaccine (Vero Cell) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the SARS-Cov-2 Vaccine (Vero Cell) market size, projected growth trends, production technologies, key applications, and end-use industries.

SARS-Cov-2 Vaccine (Vero Cell) Segment by Company

Sinopharm

Pfizer

WIBP

Sinovac Biotech

IMBCAMS,China

BIBP

SARS-Cov-2 Vaccine (Vero Cell) Segment by Type

Subunit Vaccine

Whole Virus Inactivated Vaccine

Split Vaccine

Others

SARS-Cov-2 Vaccine (Vero Cell) Segment by Application

Special Population

General Population

SARS-Cov-2 Vaccine (Vero Cell) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-Cov-2 Vaccine (Vero Cell) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SARS-Cov-2 Vaccine (Vero Cell) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-Cov-2 Vaccine (Vero Cell).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the SARS-Cov-2 Vaccine (Vero Cell) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of SARS-Cov-2 Vaccine (Vero Cell) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of SARS-Cov-2 Vaccine (Vero Cell) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of SARS-Cov-2 Vaccine (Vero Cell) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. SARS-Cov-2 Vaccine (Vero Cell) Industry Trends Table 2. SARS-Cov-2 Vaccine (Vero Cell) Industry Drivers Table 3. SARS-Cov-2 Vaccine (Vero Cell) Industry Opportunities and Challenges Table 4. SARS-Cov-2 Vaccine (Vero Cell) Industry Restraints Table 5. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Manufacturers Table 9. Global SARS-Cov-2 Vaccine (Vero Cell) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global SARS-Cov-2 Vaccine (Vero Cell) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global SARS-Cov-2 Vaccine (Vero Cell) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global SARS-Cov-2 Vaccine (Vero Cell) Manufacturers, Product Type & Application Table 13. Global SARS-Cov-2 Vaccine (Vero Cell) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global SARS-Cov-2 Vaccine (Vero Cell) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Subunit Vaccine Table 17. Major Manufacturers of Whole Virus Inactivated Vaccine Table 18. Major Manufacturers of Split Vaccine Table 19. Major Manufacturers of Others Table 20. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021-2026) & (K Units) Table 22. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2027-2032) & (K Units) Table 23. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Type (2021-2026) Table 24. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Type (2027-2032) Table 25. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2021-2026) & (K Units) Table 27. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2027-2032) & (K Units) Table 28. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Type (2021-2026) Table 29. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Special Population Table 31. Major Manufacturers of General Population Table 32. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021-2026) & (K Units) Table 34. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2027-2032) & (K Units) Table 35. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Application (2021-2026) Table 36. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Application (2027-2032) Table 37. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2021-2026) & (K Units) Table 39. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2027-2032) & (K Units) Table 40. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Application (2021-2026) Table 41. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Application (2027-2032) Table 42. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region (2021-2026) & (K Units) Table 44. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Region (2021-2026) Table 45. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2026) & (K Units) Table 49. North America SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2027-2032) & (K Units) Table 50. Europe SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2026) & (K Units) Table 52. Europe SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2027-2032) & (K Units) Table 59. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Region (2021-2026) Table 63. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Region (2027-2032) Table 64. Sinopharm Company Information Table 65. Sinopharm Business Overview Table 66. Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 68. Sinopharm Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 73. Pfizer Recent Development Table 74. WIBP Company Information Table 75. WIBP Business Overview Table 76. WIBP SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. WIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 78. WIBP Recent Development Table 79. Sinovac Biotech Company Information Table 80. Sinovac Biotech Business Overview Table 81. Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 83. Sinovac Biotech Recent Development Table 84. IMBCAMS,China Company Information Table 85. IMBCAMS,China Business Overview Table 86. IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 88. IMBCAMS,China Recent Development Table 89. BIBP Company Information Table 90. BIBP Business Overview Table 91. BIBP SARS-Cov-2 Vaccine (Vero Cell) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. BIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio Table 93. BIBP Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. SARS-Cov-2 Vaccine (Vero Cell) Distributors List Table 97. SARS-Cov-2 Vaccine (Vero Cell) Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. SARS-Cov-2 Vaccine (Vero Cell) Product Image Figure 2. Global SARS-Cov-2 Vaccine (Vero Cell) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SARS-Cov-2 Vaccine (Vero Cell) Market Size (2021-2032) & (US$ Million) Figure 4. Global SARS-Cov-2 Vaccine (Vero Cell) Sales (2021-2032) & (K Units) Figure 5. Global SARS-Cov-2 Vaccine (Vero Cell) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 SARS-Cov-2 Vaccine (Vero Cell) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Subunit Vaccine Image Figure 9. Whole Virus Inactivated Vaccine Image Figure 10. Split Vaccine Image Figure 11. Others Image Figure 12. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Type (2021-2032) Figure 15. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Type (2021-2032) Figure 18. Special Population Image Figure 19. General Population Image Figure 20. Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Application (2021-2032) Figure 23. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Application (2021-2032) Figure 26. North America SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Country (2021-2032) Figure 28. U.S. SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Country (2021-2032) Figure 33. Germany SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Country (2021-2032) Figure 40. China SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Country (2021-2032) Figure 48. Brazil SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile SARS-Cov-2 Vaccine (Vero Cell) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032) & (US$ Million) Figure 59. North America SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032) & (US$ Million) Figure 61. Europe SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. SARS-Cov-2 Vaccine (Vero Cell) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. SARS-Cov-2 Vaccine (Vero Cell) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Subunit Vaccine
  • Whole Virus Inactivated Vaccine
  • Split Vaccine
  • Others
Applications
  • Special Population
  • General Population
Companies covered
  • Sinopharm
  • Pfizer
  • WIBP
  • Sinovac Biotech
  • IMBCAMS,China
  • BIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global SARS-Cov-2 Vaccine (Vero Cell) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global SARS-Cov-2 Vaccine (Vero Cell) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global SARS-Cov-2 Vaccine (Vero Cell) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global SARS-Cov-2 Vaccine (Vero Cell) Market Dynamics
  1. 2.1 SARS-Cov-2 Vaccine (Vero Cell) Industry Trends
  2. 2.2 SARS-Cov-2 Vaccine (Vero Cell) Industry Drivers
  3. 2.3 SARS-Cov-2 Vaccine (Vero Cell) Industry Opportunities and Challenges
  4. 2.4 SARS-Cov-2 Vaccine (Vero Cell) Industry Restraints
3 SARS-Cov-2 Vaccine (Vero Cell) Market by Manufacturers
  1. 3.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Manufacturers (2021-2026)
  3. 3.3 Global SARS-Cov-2 Vaccine (Vero Cell) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global SARS-Cov-2 Vaccine (Vero Cell) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global SARS-Cov-2 Vaccine (Vero Cell) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global SARS-Cov-2 Vaccine (Vero Cell) Manufacturers, Product Type & Application
  7. 3.7 Global SARS-Cov-2 Vaccine (Vero Cell) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global SARS-Cov-2 Vaccine (Vero Cell) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 SARS-Cov-2 Vaccine (Vero Cell) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 SARS-Cov-2 Vaccine (Vero Cell) Tier 1, Tier 2, and Tier 3
4 SARS-Cov-2 Vaccine (Vero Cell) Market by Type
  1. 4.1 SARS-Cov-2 Vaccine (Vero Cell) Type Introduction
  2. 4.1.1 Subunit Vaccine
  3. 4.1.2 Whole Virus Inactivated Vaccine
  4. 4.1.3 Split Vaccine
  5. 4.1.4 Others
  6. 4.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type
  7. 4.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Type (2021-2032)
  9. 4.2.3 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Type (2021-2032)
  10. 4.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type
  11. 4.3.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Type (2021-2032)
  13. 4.3.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Type (2021-2032)
5 SARS-Cov-2 Vaccine (Vero Cell) Market by Application
  1. 5.1 SARS-Cov-2 Vaccine (Vero Cell) Application Introduction
  2. 5.1.1 Special Population
  3. 5.1.2 General Population
  4. 5.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application
  5. 5.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Application (2021-2032)
  7. 5.2.3 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Market Share by Application (2021-2032)
  8. 5.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application
  9. 5.3.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Application (2021-2032)
  11. 5.3.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Application (2021-2032)
6 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region
  1. 6.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region (2021-2032)
  3. 6.2.1 Global SARS-Cov-2 Vaccine (Vero Cell) Sales by Region (2021-2026)
  4. 6.2.2 Global SARS-Cov-2 Vaccine (Vero Cell) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region
  1. 7.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region
  2. 7.1.1 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region (2021-2026)
  4. 7.1.3 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue by Region (2027-2032)
  5. 7.1.4 Global SARS-Cov-2 Vaccine (Vero Cell) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032)
  8. 7.2.2 North America SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032)
  11. 7.3.2 Europe SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa SARS-Cov-2 Vaccine (Vero Cell) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sinopharm
  2. 8.1.1 Sinopharm Company Information
  3. 8.1.2 Sinopharm Business Overview
  4. 8.1.3 Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sinopharm SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  6. 8.1.5 Sinopharm Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 WIBP
  14. 8.3.1 WIBP Company Information
  15. 8.3.2 WIBP Business Overview
  16. 8.3.3 WIBP SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 WIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  18. 8.3.5 WIBP Recent Developments
  19. 8.4 Sinovac Biotech
  20. 8.4.1 Sinovac Biotech Company Information
  21. 8.4.2 Sinovac Biotech Business Overview
  22. 8.4.3 Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sinovac Biotech SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  24. 8.4.5 Sinovac Biotech Recent Developments
  25. 8.5 IMBCAMS,China
  26. 8.5.1 IMBCAMS,China Company Information
  27. 8.5.2 IMBCAMS,China Business Overview
  28. 8.5.3 IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IMBCAMS,China SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  30. 8.5.5 IMBCAMS,China Recent Developments
  31. 8.6 BIBP
  32. 8.6.1 BIBP Company Information
  33. 8.6.2 BIBP Business Overview
  34. 8.6.3 BIBP SARS-Cov-2 Vaccine (Vero Cell) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BIBP SARS-Cov-2 Vaccine (Vero Cell) Product Portfolio
  36. 8.6.5 BIBP Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 SARS-Cov-2 Vaccine (Vero Cell) Value Chain Analysis
  2. 9.1.1 SARS-Cov-2 Vaccine (Vero Cell) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 SARS-Cov-2 Vaccine (Vero Cell) Production Mode & Process
  6. 9.2 SARS-Cov-2 Vaccine (Vero Cell) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 SARS-Cov-2 Vaccine (Vero Cell) Distributors
  9. 9.2.3 SARS-Cov-2 Vaccine (Vero Cell) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst